Your browser doesn't support javascript.
loading
A Double-Edged Sword-Cardiovascular Concerns of Potential Anti-COVID-19 Drugs.
Yu, Wen-Liang; Toh, Han Siong; Liao, Chia-Te; Chang, Wei-Ting.
  • Yu WL; Department of Intensive Care Medicine, Chi Mei Medical Center, Tainan, Taiwan.
  • Toh HS; Department of Medicine, School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan.
  • Liao CT; Department of Intensive Care Medicine, Chi Mei Medical Center, Tainan, Taiwan.
  • Chang WT; Institute of Clinical Medicine, College of Medicine, National Cheng Kung University, Tainan, Taiwan.
Cardiovasc Drugs Ther ; 35(2): 205-214, 2021 Apr.
Article en En | MEDLINE | ID: mdl-32557011
ABSTRACT
Coronavirus disease 2019 (COVID-19) is a pandemic infection caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). COVID-19 significantly affects multiple systems including the cardiovascular system. Most importantly, in addition to the direct injury from the virus per se, the subsequent cytokine storm, an overproduction of immune cells and their activating compounds, causes devastating damage. To date, emerging anti-SARS-CoV-2 treatments are warranted to control epidemics. Several candidate drugs have been screened and are currently under investigation. These primarily include antiviral regimens and immunomodulatory regimens. However, beyond the anti-SARS-CoV-2 effects, these drugs may also have risks to the cardiovascular system, especially altering cardiac conduction. Herein, we review the cardiovascular risks of potential anti-COVID-19 drugs.
Asunto(s)
Palabras clave

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Antivirales / Sistema Cardiovascular / Cardiotoxicidad / SARS-CoV-2 / COVID-19 / Tratamiento Farmacológico de COVID-19 / Factores Inmunológicos Tipo de estudio: Etiology_studies / Risk_factors_studies Límite: Humans Idioma: En Año: 2021 Tipo del documento: Article

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Antivirales / Sistema Cardiovascular / Cardiotoxicidad / SARS-CoV-2 / COVID-19 / Tratamiento Farmacológico de COVID-19 / Factores Inmunológicos Tipo de estudio: Etiology_studies / Risk_factors_studies Límite: Humans Idioma: En Año: 2021 Tipo del documento: Article